Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16422536 | 1.00 | SLC6A3 (0.49) | SLC6A3KMT2APTGS2DRD2DRD4 | |
| SCHEMBL4614574 | 1.00 | SLC6A3 (0.49) | SLC6A3KMT2APTGS2DRD2DRD4 | |
| SCHEMBL2246366 | 0.87 | OPRK1 (0.49) | KMT2AHSD11B1OPRK1OPRD1OPRM1 | |
| SCHEMBL2242094 | 0.87 | OPRK1 (0.49) | KMT2AHSD11B1OPRK1OPRD1OPRM1 | |
| SCHEMBL6042399 | 0.86 | KMT2A (0.49) | KMT2ADRD2DRD4DRD3HSD11B1 | |
| SCHEMBL16423480 | 0.84 | KMT2A (0.51) | SLC6A3KMT2APTGS2HSD11B1OPRK1 | |
| SCHEMBL16423136 | 0.82 | SLC6A3 (0.41) | SLC6A3KMT2ADRD2DRD4DRD3 | |
| SCHEMBL16423307 | 0.82 | RORC (0.42) | SLC6A3KMT2AOPRK1OPRD1OPRM1 | |
| SCHEMBL4666899 | 0.81 | KMT2A (0.48) | SLC6A3KMT2APTGS2HSD11B1OPRK1 | |
| SCHEMBL4919416 | 0.81 | ALK (0.48) | SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2832728-B1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL IND LTD (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1928460-A2 | MC4R-AGONISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | Pfizer Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| EP-1912968-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | Pfizer Limited (GB) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007015157-A2 | MC4R-AG0NISTS FOR THE TREATMENT OF URINARY TRACT DYSFUNCTION | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007015162-A1 | PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS | PFIZER LIMITED (GB) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | SLC6A3 1030/4885KMT2A 3354/4885PTGS2 4377/4885 |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | SLC6A3 783/4885KMT2A 3129/4885PTGS2 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.